← All Compass Therapeutics, INC filings

Compass Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
CMPX
Compass Therapeutics, INC
10-K: Compass Therapeutics Reports Positive BTC Trial Data, Bolsters Pipeline
Compass Therapeutics, Inc. announced positive Phase 2/3 trial results for tovecimig in biliary tract cancer, alongside pipeline advancements and new executive hires, while reporting increased net losses for 2025.
NASDAQ
CMPX
Compass Therapeutics, INC
10-K: Compass Therapeutics Reports FY 2024 Results, Highlights Pipeline Progress
Compass Therapeutics files its 10-K report for FY 2024, detailing its financial position and progress in developing antibody-based therapeutics for oncology.
NASDAQ
CMPX
Compass Therapeutics, INC
10-K: Compass Therapeutics Announces Executive Employment Agreements and 10-K Filing
Compass Therapeutics has formalized new employment agreements with key executives and filed its annual 10-K report, outlining financial performance and strategic direction.